Papers by Meletios Α. Dimopoulos
Page 9 · newest first
- Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular MedicineThrombosis and Haemostasis · 2020
- The Genomic Profile of Pregnancy-Associated Breast Cancer: A Systematic ReviewFrontiers in Oncology · 2020
- Emerging drugs for the treatment of Waldenström macroglobulinemiaExpert Opinion on Emerging Drugs · 2020
- Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapseLeukemia · 2020
- Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 studyBlood Cancer Journal · 2020
- Daratumumab‐based therapy for patients with monoclonal gammopathy of renal significanceBritish Journal of Haematology · 2020
- Next generation flow cytometry for MRD detection in patients with AL amyloidosisAmyloid · 2020
- The emerging role of BET inhibitors in breast cancerThe Breast · 2020
- Systemic AL Amyloidosis: Current Approaches to Diagnosis and ManagementHemaSphere · 2020
- A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN studyBlood · 2020
- Bortezomib, Melphalan, and Dexamethasone for Light-Chain AmyloidosisJournal of Clinical Oncology · 2020
- Predictors of adverse prognosis in COVID‐19: A systematic review and meta‐analysisEuropean Journal of Clinical Investigation · 2020
- Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosisAmyloid · 2020
- Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor CarfilzomibInternational Journal of Molecular Sciences · 2020
- Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple MyelomaCancers · 2020
- The current role of BTK inhibitors in the treatment of Waldenstrom’s MacroglobulinemiaExpert Review of Anticancer Therapy · 2020
- Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myelomaAnnals of Hematology · 2020
- Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) TrialBritish Journal of Cancer · 2020
- Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemicBritish Journal of Haematology · 2020
- Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease ProgressionJournal of Clinical Oncology · 2020
- Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysisLeukemia · 2020
- Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS SyndromeHemaSphere · 2020
- A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myelomaLeukemia · 2020
- Oncology during the COVID‑19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients (Review)Oncology Letters · 2020
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 studyThe Lancet Haematology · 2020
- Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myelomaLeukemia · 2020
- Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agentsBlood Cancer Journal · 2020
- Hematological findings and complications of COVID‐19American Journal of Hematology · 2020
- Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myelomaLeukemia & lymphoma/Leukemia and lymphoma · 2020
- Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysisBlood Cancer Journal · 2020
- Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRdExpert Review of Hematology · 2020
- Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myelomaBlood Advances · 2020
- Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myelomaBlood Cancer Journal · 2020
- Clinical biomarkers directing the management of patients with colon and lung cancer (beyond oncogene-addicted NSCLC)Forum of Clinical Oncology · 2020
- Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trialsLeukemia · 2020
- Comparison of efficacy from two different dosing regimens of bortezomib: an exposure–response analysisBritish Journal of Haematology · 2020
- Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaBlood Cancer Journal · 2020
- Real‐world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco‐Israeli collaborative myeloma working groupAmerican Journal of Hematology · 2020
- Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 studyLeukemia · 2020
- Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implicationsAmyloid · 2020
- Efficacy of Panobinostat for the Treatment of Multiple MyelomaJournal of Oncology · 2020
- Solid Organ Transplantation in AmyloidosisActa Haematologica · 2020
- Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trialEuropean Journal Of Haematology · 2019
- Prognostic role of microRNAs in breast cancer: A systematic reviewOncotarget · 2019
- Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study designFuture Oncology · 2019
- Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasoneBlood Advances · 2019
- Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)Blood · 2019
- Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had PlasmacytomasBlood · 2019
- Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myelomaExpert Review of Anticancer Therapy · 2019
- Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trialsLeukemia & lymphoma/Leukemia and lymphoma · 2019